Novo Nordisk A/S Common Stock (NVO)
64.49
-1.57 (-2.38%)
NYSE · Last Trade: Apr 15th, 11:55 PM EDT
FDA and Novo Nordisk warn about counterfeit Ozempic in the U.S. with fake serial numbers, posing risks due to unknown contents and unverified sterility.
Via Benzinga · April 15, 2025
Skye shares surge after new data shows nimacimab reduces weight over 30% with tirzepatide, with stable potency and promising obesity treatment potential.
Via Benzinga · April 15, 2025
Mounjaro's launch in India sparks a surge in patient demand as Eli Lilly gains a market edge ahead of Novo Nordisk and upcoming generic competition.
Via Benzinga · April 15, 2025
The company said the seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits, 51746517.
Via Stocktwits · April 14, 2025
Pfizer bows, but is not entirely out of the GLP-1 race.
Via The Motley Fool · April 14, 2025
Via Benzinga · April 14, 2025
Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition.
Via Benzinga · April 14, 2025
From vaccines to fluoride and beef tallow, here's where Robert F. Kennedy Jr. is making changes to health care.
Via Investor's Business Daily · April 10, 2025
Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?
Via MarketBeat · April 10, 2025
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.
Via Benzinga · April 9, 2025
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.
Via Investor's Business Daily · April 9, 2025
CMS finalizes 2026 Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.
Via Benzinga · April 8, 2025
However, Morgan Stanley sees limited impact on Lilly from the CMS decision as the proposed coverage appeared to apply only to a subset of the Medicare obesity population
Via Stocktwits · April 8, 2025
Needham hosted an expert to discuss potential impact of trade tariffs and personnel changes on healthcare equities. Generic drug market may be negatively affected.
Via Benzinga · April 7, 2025
NOVO-NORDISK A/S-SPONS ADR may be an undervalued stock option. NYSE:NVO retains a strong financial foundation and an attractive price tag.
Via Chartmill · April 5, 2025
The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs.
Via Investor's Business Daily · April 4, 2025
Via The Motley Fool · April 2, 2025
It's true, the company can sell Lilly's tirzepatide. But that doesn't mean patients will buy it.
Via Investor's Business Daily · April 2, 2025
Novo Nordisk saw its stock drop 21% year-to-date, pressured by weaker-than-expected obesity drug trial results.
Via Benzinga · April 2, 2025
The company said that its earnings consist of income from dividends and the share repurchase programmes of Novo Group companies Novo Nordisk A/S and Novonesis A/S, as well as returns from its investment portfolio.
Via Stocktwits · April 2, 2025
Via The Motley Fool · April 2, 2025
Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli Lilly And Co's (NYSE:LLY) Zepbound through its Telehealth platform.
Via Benzinga · April 1, 2025
The deal allows Hims & Hers to sell Eli Lilly's Zepbound on its telehealth platform.
Via Investor's Business Daily · April 1, 2025